CMPS — COMPASS Pathways plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: GB
- Exchange: NASDAQ Global Select
- Employees: 166
- Website: https://compasspathways.com
Latest SEC filings for CMPS
- S-3ASR — 2026-08-05
- 8-K — 2026-08-05
- 10-Q — 2026-08-05
- 8-K — 2026-07-07
- 8-K — 2026-05-28
- SCHEDULE 13G/A — 2026-05-15
- 10-Q — 2026-05-13
- 8-K — 2026-05-13
- ARS — 2026-04-15
- 10-K — 2026-03-24
Latest CMPS news
- — Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- — Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages (defenseworld.net)
- — Compass Pathways Appoints Kelley Boucher as Chief People Officer
Educational tool only — not investment advice.